Dexrazoxane Reduces Short-Term Anthracycline-Associated Cardiac Dysfunction in Pediatric AML
Pediatric patients with AML may benefit from dexrazoxane as a cardioprotectant during first-line anthracycline therapy.
Pediatric patients with AML may benefit from dexrazoxane as a cardioprotectant during first-line anthracycline therapy.